61 related articles for article (PubMed ID: 26011836)
1. The configuration of biomolecular markers in cancer of the uterine cervix. Personalized therapy. Monitoring and prognosis.
Prunoiu VM; Marincaş MA; Cirimbei C; Ionescu S; Zurac S; Radu M; Nicolaescu R; Brătucu E; Straja ND;
Chirurgia (Bucur); 2015; 110(2):144-50. PubMed ID: 26011836
[TBL] [Abstract][Full Text] [Related]
2. The place of radiofrequency ablation in the multimodal treatment of cervical cancer. Our experience.
Marincaş MA; Prunoiu VM; Ionescu S; Brătucu E
Chirurgia (Bucur); 2014; 109(2):168-73. PubMed ID: 24742405
[TBL] [Abstract][Full Text] [Related]
3. Molecular factors and criteria for predicting the response to neoadjuvant treatment in patients with esophageal squamous cell carcinoma (ESCC) -- responder/non-responder.
Predescu D; Gheorghe M; Boeriu M; Constantin A; Iosif C; Anghel R; Constantinoiu S
Chirurgia (Bucur); 2012; 107(5):583-90. PubMed ID: 23116831
[TBL] [Abstract][Full Text] [Related]
4. [Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution].
Stoenescu TM; Ivan LD; Stoenescu N; Azoicăi D
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):485-92. PubMed ID: 21870745
[TBL] [Abstract][Full Text] [Related]
5. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
6. [Impact of squamous cell carcinoma antigen in patients with recurrent squamous cell carcinoma of the uterine cervix].
Ma SK; Wu LY; Sun YC; Li B; Zhang HT
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):13-7. PubMed ID: 18366925
[TBL] [Abstract][Full Text] [Related]
7. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.
Trejo-Becerril C; Oñate-Ocaña LF; Taja-Chayeb L; Vanoye-Carlo A; Cetina L; Duenas-Gonzalez A
BMC Cancer; 2005 Jun; 5():65. PubMed ID: 15982417
[TBL] [Abstract][Full Text] [Related]
8. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients.
Li J; Cheng H; Zhang P; Dong Z; Tong HL; Han JD; Guo F; Tian YP
Clin Chim Acta; 2013 Sep; 424():292-7. PubMed ID: 23850705
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix.
Silva-Filho AL; Traiman P; Triginelli SA; Reis FM; Pedrosa MS; Miranda D; Abreu ES; Macarenco RS; Cunha-Melo JR
Gynecol Oncol; 2004 Dec; 95(3):646-54. PubMed ID: 15581977
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum squamous cell carcinoma antigen in the diagnosis, treatment and prognosis of cervical squamous cell carcinoma].
Luan XM; Zhang Y; Wang SZ; Wang N; Li W; Zhang Q; Wei H; Zhang SL
Zhonghua Yi Xue Za Zhi; 2012 May; 92(19):1330-3. PubMed ID: 22883121
[TBL] [Abstract][Full Text] [Related]
12. Expression of BDNF, TrkB, and p53 in early-stage squamous cell carcinoma of the uterine cervix.
Moon A; Won KY; Lee JY; Kang I; Lee SK; Lee J
Pathology; 2011 Aug; 43(5):453-8. PubMed ID: 21670725
[TBL] [Abstract][Full Text] [Related]
13. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
14. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
Geyer H; Schwörer D; Pfleiderer A
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
16. [The course of squamous cell cancer antigen in chemotherapy as a prognostic criterion in cervix cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Gynakol Rundsch; 1989; 29 Suppl 2():411-2. PubMed ID: 2613066
[No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.
Serur E; Mathews RP; Gates J; Levine P; Maiman M; Remy JC
Gynecol Oncol; 1997 May; 65(2):348-56. PubMed ID: 9159350
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
[TBL] [Abstract][Full Text] [Related]
20. Serum evaluation of P53 protein in patients with gynaecological cancer.
Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV
Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
